inSPIRE

inSPIRE improves peptide-spectrum match (PSM) identification by rescoring database search results using Prosit MS spectral predictions to increase accuracy and sensitivity of mass spectrometry-based proteomic analyses.


Key Features:

  • Spectral Prediction Integration: Uses Prosit MS spectral predictions to inform rescoring by comparing predicted spectra with experimental spectra for each PSM.
  • Compatibility with Database Search Engines: Accepts results from common database search engines for downstream rescoring.
  • Large-Scale Rescoring Capability: Supports rescoring of mass spectrometry data from multiple search files simultaneously.
  • Enhanced Sensitivity to Amino Acid Variations: Detects minor differences in amino acid residue positions to differentiate peptides, including those from nonspecific cleavage events.
  • Versatility Across Sample Types: Applicable to tryptic proteome digests and immunopeptidomes.

Scientific Applications:

  • Immunopeptidomics: Boosts PSM identification rates to improve characterization of peptide repertoires presented by major histocompatibility complex (MHC) molecules.
  • Noncanonical Peptide Identification: Enhances detection of noncanonical peptides that do not follow typical proteolytic cleavage patterns.
  • Tryptic Proteome Analysis: Improves peptide identification in tryptic proteome digests for general proteomic studies.

Methodology:

inSPIRE uses Prosit MS spectral predictions to rescore database search results, integrates additional scoring metrics, supports rescoring of multiple search files simultaneously, and has been benchmarked on ground truth datasets.

Topics

Details

License:
Apache-2.0
Cost:
Free of charge
Tool Type:
command-line tool
Operating Systems:
Mac, Linux, Windows
Added:
2/24/2023
Last Updated:
11/24/2024

Operations

Publications

Cormican JA, Horokhovskyi Y, Soh WT, Mishto M, Liepe J. inSPIRE: An Open-Source Tool for Increased Mass Spectrometry Identification Rates Using Prosit Spectral Prediction. Molecular & Cellular Proteomics. 2022;21(12):100432. doi:10.1016/j.mcpro.2022.100432. PMID:36280141. PMCID:PMC9720494.

PMID: 36280141
PMCID: PMC9720494
Funding: - Cancer Research UK: A29686, C67500 - European Research Council: 945528 - Horizon 2020 MSCA: 101065466